For the true nerds: 48-year-old right-handed man with MS with right visual field loss with alexia without agraphia. He improved but had mild reading difficulty journals.sagepub.com/doi/epdf/10....
Medication for Multiple Sclerosis Fatigue Explained by Neurologist youtu.be/nWONMHdCQvo?...
43 year old woman with dizziness, hiccups, nausea. MRI shows THIS lesion in the medulla! anti AQP4 neuromyelitis optica? No! Hint: her father has progressive gait decline and motor/sensory neuropathy. Diagnosis?
Dr Terry Wahls Deserves More Respect youtube.com/shorts/Dd3WD...
If you take a b-cell depleting drug (ocrevus, rituximab kesimpta) for multiple sclerosis while breastfeeding, will your infant's b-cell be affected? In this study (n=10), only one infant had b-cell counts below the 5th percentile. pubmed.ncbi.nlm.nih.gov/42226810/
Potential multiple sclerosis treatments targeting Epstein-Barr virus. One of the authors is a colleague of mine, Dr. Hannah Zhao-Fleming www.frontiersin.org/journals/imm...
43-year-old woman with headache and left inferior quadrantanopsia and right superior quadrantanopsia. MRI shows THIS! Diagnosis?
Vitamin D for multiple sclerosis. This network meta-analysis of 32 randomized trials suggests vitamin D is modestly effective and was associated with 20% few relapses and slightly less disability (0.22 points lower on the EDSS scale). www.clinicalnutritionjournal.com/article/S026...
Siponimod (mayzent) in secondary progressive MS reduced EDSS ≥ 7.0 (requiring a wheelchair) by 40% (from the EXPAND randomized trial against placebo) (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.41–0.88; p = 0.009) onlinelibrary.wiley.com/doi/10.1111/...
Dr. John Corboy on the risk of relapse/new MRI lesions in people who stop disease modifying therapy and observational studies such as DISCOMS and DOTMS. He also discussed extended interval dosing with b-cell depleters. www.neurologylive.com/view/discont...
Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system,
with limited effective adjuvant therapies beyond immunomodulatory agents. Vitamin
D supplementation has been pro...
www.clinicalnutritionjournal.com
Siponimod lowered the risk of wheelchair use in SPMS patients compared to placebo, especially in those with active disease. Time to wheelchair is a key metric for evaluating treatment in SPMS.
The professor of neurology at the University of Colorado discussed evidence from DISCOMS and other trials on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis...
